Latest market news

One year has passed since the massive crash in the cryptocurrency market on October 10, 2025, and liquidity in Bitcoin and Ethereum is recovering, CoinDesk reported based on its analysis of buy and sell orders on major centralized exchanges. The study found that the value of buy and sell orders near the current prices of both assets exceeded levels on the day of the crash, while order values for the other altcoins examined continued to decline and spot trading volumes also fell below levels seen at the time, showing uneven recovery across the market. The sharp sell-off on October 10, 2025 came after U.S. President Donald Trump announced 100% tariffs on Chinese goods, with BTC falling from around $122,600 to briefly below $105,000, triggering the forced liquidation of more than $19 billion in leveraged positions in a single day. As of October 7, BTC orders within 1% above and below the current price totaled about $11.7 million, up roughly 75% from the day of the crash, while ETH also rose about 75% within the same range to reach about $5.3 million. Meanwhile, among the altcoins examined, order values within 5% above and below the price fell by about one-third from the start of 2025 to about $2 million, and orders within 1% declined by about one-sixth. Weekly spot trading volume on centralized exchanges averaged about $279 billion over the four weeks through September 27, down about two-thirds from about $801 billion in the week of the crash.

Enova International subsidiary OnDeck has rolled out fully automated small business loan approvals powered by AI and machine learning. The system is designed to verify applicants and generate stipulation free offers within minutes, reducing reliance on manual review, and OnDeck is applying the new automation directly to its core lending platform to speed up processing for small business borrowers. Enova International positions itself as a technology-driven consumer finance provider, using data and analytics to offer online credit products to individuals and businesses across the US, Brazil, and other markets. The key signpost to watch is the share of small business applications that move to fully automated, stipulation free approvals over the next few quarters, paired with stable loss metrics in Enova's regular credit updates.

Tenable Holdings has paired a fresh AI security rollout with a high profile board appointment, giving investors new information on both product direction and governance in the AI driven cybersecurity market. The news lands on a rising share price, with a 1-day share price return of 6.61% and a 30-day share price return of 38.13% feeding into an 82.97% year-to-date share price gain, even though the 3-year and 5-year total shareholder returns of 2.87% and 18.21% respectively show a weaker longer run record. Tenable Holdings closed at $41.59 while the most followed narrative pegs fair value at $35.35, an 18% overvaluation. The company's ability to consolidate multiple asset types, including VM, cloud, identity, OT and AI security, in a single platform is resulting in larger deal sizes and growing enterprise adoption, directly impacting top-line growth and average selling prices. Still, heavy exposure to U.S. Federal and public sector budgets, alongside intense platform competition from larger cybersecurity vendors, could quickly challenge the momentum story.

International Business Machines announced a new collaboration with Zscaler and Red Hat to tighten application security for enterprise clients. The joint effort combines IBM and Red Hat software platforms with Zscaler threat intelligence to provide real-time protections at the application layer. The partners plan to coordinate vulnerability discovery, automated policy updates, and validated software remediation workflows for shared customers. International Business Machines is a US-based IT group with a reported market value of about $214.0 billion, and its integrated solutions and services span the Americas, Europe, the Middle East, Africa and the Asia Pacific. One figure to watch is how much of IBM's reported US$24.6b of annual recurring revenue comes from security and hybrid cloud offerings connected to Red Hat and Zscaler style deployments.

CVS Health is expanding its pharmacy-focused format by opening nearly 20 smaller neighborhood locations across the United States in 2026, including a new Roxbury site in the Boston area. The expansion comes as recent headlines have sent mixed signals for investors, with Medicare Advantage star rating setbacks and a legal probe weighing on sentiment, while an extended Cardinal Health distribution deal and a reaffirmed dividend provide a steadier backdrop. Even after a one-day share price decline of 1.87% and a 30-day share price return down 8.98%, the year-to-date share price return of 7.53% and a one-year total shareholder return of 14.11% indicate that longer term holders have still seen gains as shorter term momentum has faded. On the most followed view, CVS Health screens as undervalued, with a fair value of $124 against a last close of $86.16. The company has raised full-year guidance twice through the first half of 2026, Aetna's medical benefit ratio has improved, cash flow is running well ahead of plan, and all three operating segments are growing, though the story could break if Aetna's medical cost trend runs hotter than expected or if pharmacy benefit reforms compress Health Services earnings faster than planned.

Chewy posted second quarter fiscal 2026 results with adjusted earnings matching forecasts and net sales ahead of expectations, then raised its outlook as Autoship and AI driven efficiencies took center stage. The update lands after a tough stretch for the stock, with the share price down 43.42% year to date and the 1-year total shareholder return declining 51.45%, even as the 3-year total shareholder return remains positive at 11.47%. A 7-day share price return of 4.29% suggests investors are tentatively reassessing the balance between future growth potential and perceived risk at the current US$18.95 level. Chewy is priced at $18.95 against a widely followed fair value estimate of $28.64 that uses an 8.56% discount rate, a gap that turns the Autoship, pet health and AI cost story into a valuation question rather than just an earnings story. On the earnings multiple, Chewy trades at 27.8x earnings compared with a fair ratio of 20.7x, the US Specialty Retail average of 16.5x and a 15.6x peer average, a richer tag that increases the risk any stumble in the thesis affects the multiple first.

Lockheed Martin declared a quarterly dividend of $3.60 per share, a 4.3% increase from its prior dividend of $3.45. The forward yield comes to 2.83%. The dividend is payable Dec. 31 to shareholders of record as of Dec. 1, with an ex-dividend date of Dec. 1.

Startale Japan has begun offering digital retail bonds with a 5% annual interest rate. Interest payments and redemption will use JPYSC, a trust-type yen-denominated stablecoin. The bonds are managed on infrastructure built with Hyperledger Fabric, while JPYSC is issued on Ethereum, meaning the bonds and the funds for interest payments do not sit on the same blockchain. The company sees the connection costs of horizontal specialization as a challenge, and has set out a vertical integration strategy that provides everything from base layers such as Strium, a blockchain dedicated to on-chain finance, through to JPYSC and wallets. This initiative is positioned as the current form of efforts to promote the adoption of JPYSC.

SpaceX has agreed to acquire Grain Management's nationwide portfolio of low-band wireless spectrum licenses, advancing the Elon Musk-led company's effort to compete with Verizon Communications Inc., AT&T Inc. and T-Mobile Us Inc. The agreement covers spectrum in the 800 MHz band and remains subject to approval by the Federal Communications Commission; SpaceX says the licenses will complement Starlink Mobile's existing satellite capabilities with terrestrial connectivity. The FCC has also authorized SpaceX to deploy 15,000 next-generation Starlink satellites optimized for mobile connectivity, and together the spectrum acquisition and satellite expansion move the company closer to offering a more comprehensive mobile service. Musk made his ambitious prediction in an Oct. 8 post on X, saying he sees a path to SpaceX being worth orders of magnitude more than the current Earth economy. Investors should watch for regulatory approval, launch timelines, pricing announcements and evidence of customer adoption, as the next test is whether SpaceX can persuade consumers to switch networks or pay less to stay connected.

Certara's fair value estimate has edged up to US$8.71 from US$8.19, with analyst price targets clustering in the US$9 to US$10 range ahead of upcoming results. UBS resumed coverage of Certara with a Neutral rating and a US$10 price target, while Barclays lifted its target from US$7.50 to US$9 and Baird moved from US$6 to US$7. Revenue growth expectations have shifted from a decline of 0.64% to an increase of 1.49%, while the net profit margin is reported at 3.76% on both the previous and updated figures and the future P/E has changed from 87.9x to 94.4x. Barclays describes an "extremely tough setup" for life science and diagnostic stocks, and UBS says it wants more evidence of a software revenue recovery before taking a more positive view. The discount rate is broadly unchanged, moving from 8.57% to 8.59%.

Abbott Laboratories introduced Ensure Max Protein 3-in-1 Muscle Support, a combined protein, creatine, and HMB powder that is NSF certified and targets muscle building, recovery, and preservation for everyday active consumers and athletes. The launch expands Abbott's nutrition portfolio beyond devices and diagnostics into a broader performance-focused supplement offering, edging the company into a space where firms like Nestlé Health Science and Danone are already active. The product lands in Abbott's Nutrition segment, which the company's narrative casts as rebuilding trust and profitability after legal issues while medical technology and diagnostics do the heavy lifting for future earnings. Relative to large-ticket catalysts such as Libre, electrophysiology tools and Cancer Diagnostics, Ensure Max Protein looks more like incremental support for Nutrition recovery than a central earnings driver, especially with analysts still flagging legal exposure and margin pressure in the segment.

Foxconn Industrial Internet announced that the U.S. International Trade Commission declared on October 9 local time that it has formally launched a Section 337 investigation into patent infringement claims filed by Vicor Corporation of the United States. Vicor alleges that Foxconn Industrial Internet and its controlled subsidiaries infringed one of its patents for a vertical power delivery system. Foxconn Industrial Internet said that after an internal review, the products involved in this investigation are still in the internal validation and evaluation stage, and will not have a material impact on the company's current production, operations, or financial performance.

Jinbei Automobile Co., Ltd. has entered the implementation stage for its 2026 interim equity distribution, paying a cash dividend of 0.01 yuan per share before tax. Based on total share capital of 1,304,558,558 shares, the total cash dividend amounts to 13,045,585.58 yuan. The record date is October 12, 2026, and both the ex-dividend date and the cash dividend payment date are October 13. This is Jinbei Auto's second cash payout to shareholders in 2026, following the 2025 annual equity distribution implemented in May, which paid 0.023 yuan per share before tax, totaling 30,004,846.83 yuan. Combined, the company's cumulative cash dividends for the year are approximately 43.05 million yuan, equivalent to 0.033 yuan per share. Based on the closing price of 3.58 yuan on October 9, the corresponding dividend yield is about 0.92 percent, with this interim dividend alone corresponding to a yield of about 0.28 percent. Jinbei Auto listed on the Shanghai Stock Exchange in 1992 and had never paid a cash dividend for more than thirty years after listing, earning it the nickname of a rare iron rooster among A-share companies. The turning point came in 2025, when the company used surplus reserves and capital reserves to make up accumulated losses, clearing the legal obstacles to dividends, and proposed a dividend plan for the first time in its 2025 annual report. In the first half of 2026, the company achieved operating revenue of 2.349 billion yuan, up about 10.2 percent year on year, while net profit attributable to shareholders of the listed company was 92.91 million yuan, down about 9.7 percent year on year. This interim dividend of 13.05 million yuan accounts for 14.04 percent of first-half net profit attributable to the parent company. The company's operating structure still has hidden concerns. The 2025 annual report shows that sales to the top five customers accounted for 90.23 percent of total revenue, of which sales to BMW Brilliance accounted for 83.78 percent, indicating extremely high customer concentration. From a market-wide perspective, Jinbei Auto is a microcosm of the expanding interim dividend ranks in the A-share market. The number of companies paying interim dividends in 2026 has hit another record high, with total proposed cash payouts exceeding 700 billion yuan.

New China Life disclosed a stake-building announcement on October 9, increasing its holding in Guotai Haitong H-shares by 9.9596 million shares through New China Asset Management. Together with persons acting in concert New China Asset Management and New China Asset Management Hong Kong, the combined holding rose to 710 million shares, representing 20.24% of Guotai Haitong's H-share capital. This marks the first time a domestic insurer has pushed its stake in a single brokerage's H-shares above 20% of that brokerage's H-share capital. Based on Guotai Haitong's total share capital of 17.581 billion shares, the New China Life group's stake is about 4.04%, enough to rank as the second-largest single shareholder of this brokerage flagship. Hong Kong Stock Exchange disclosures show that the New China Life group's holding in Guotai Haitong H-shares has risen step by step since May this year, breaking above 16% on May 15, above 17% on July 15, above 18% on September 3, above 19% on September 16, and reaching 20% on September 29, with the holding increasing from 560 million shares to 710 million shares. The funding source for this increase was insurance liability reserves. As of September 29, the book balance of New China Life's holding in Guotai Haitong H-shares was 8.97 billion yuan, accounting for 0.48% of New China Life's total assets at the end of the second quarter of 2026. Since 2026, insurer stake-building activity has cooled noticeably. Only five insurers have made a combined seven stake-building announcements in listed companies this year, less than 30% of the more than 30 stake-building announcements by 13 insurers in the same period of 2025. However, the balance of insurance funds invested in stocks and securities investment funds has crossed the 6 trillion yuan mark for the first time, with the allocation ratio approaching 16%, a record high, and has now risen quarter-on-quarter for eight consecutive quarters.

Baili Tianheng announced that the company recently received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration. The clinical trial of its self-developed, world-first bispecific antibody drug conjugate Yizekang, also known as luncoitab, in combination with radiotherapy for locally advanced unresectable head and neck squamous cell carcinoma and other solid tumors has been approved. To date, the drug has initiated more than 45 clinical trials in China and the United States, including 20 Phase III clinical studies, and 9 indications have been included in the breakthrough therapy designation list by the Center for Drug Evaluation.

As unauthorized access to companies surges, electronics giants offering cyber defense services are receiving a flood of consultations and inquiries. In September, Hitachi launched a service that uses advanced AI models from U.S. firms such as Anthropic and OpenAI to provide end-to-end support spanning risk assessment, monitoring, and recovery. Fujitsu announced its cyber defense strategy in late August, and inquiries from client companies have poured in since then, increasing further in recent days, prompting it to establish a specialized organization of about 100 people effective October 1. NEC began offering a service in late September for financial institutions, manufacturers, and distributors that uses AI to automatically analyze risks and formulate response policies. Each company is strengthening its systems in anticipation of sophisticated AI-driven cyberattacks, and demand appears set to keep expanding.

Amazon.com is reportedly considering moving roughly $8 billion of Nvidia Grace Blackwell chips into a special-purpose vehicle financed by outside investors and then leasing the hardware back, a structure that would make part of its AI buildout more asset-light as capital spending is expected to reach $220 billion this year. AWS revenue rose 37% to $42.2 billion in the second quarter, its fastest growth in more than four years, and contract backlog reached $496 billion, while CEO Andy Jassy said the company still lacks enough capacity to meet demand. Trailing-12-month free cash flow swung to negative $7.6 billion from positive $18.2 billion a year earlier as infrastructure spending accelerated. Amazon trades at 23.64 times forward earnings, and Tigress Financial recently raised its target to $385 from $315, arguing earnings from the investment cycle are approaching an inflection point where they grow faster than operating capital. The proposal also raises the question of residual chip value, since Grace Blackwell will eventually be superseded by Vera Rubin while Amazon assumes semiconductor generations remain useful for at least five years.

Merck announced that remigromig, an investigational tri-specific antibody that activates the Wnt pathway, met the primary endpoint in the pivotal Phase 2b/3 BRUNELLO trial in adults with diabetic macular edema, with both dose arms demonstrating non-inferiority in mean change from baseline in best corrected visual acuity at one year versus monthly 0.5mg ranibizumab. Mean BCVA gains at Year 1 were +9.1 letters with remigromig 0.5 mg and +8.7 letters with remigromig 0.8 mg, compared with +11.8 letters with ranibizumab, and no secondary endpoints demonstrated superiority to ranibizumab. The company said remigromig is the first biologic with a novel mechanism of action to demonstrate non-inferior visual acuity compared with anti-VEGF therapy in a pivotal DME trial, and the first new mechanism of action in more than 20 years to do so. Adverse events related to proliferative diabetic retinopathy occurred more frequently with remigromig than with ranibizumab, at 6.7% and 6.1% for the 0.5 mg and 0.8 mg arms versus 0.9%, and treatment discontinuations due to adverse events were also higher, at 4.9% and 4.5% versus 0.9%. The results, presented at the American Academy of Ophthalmology 2026 Annual Meeting in New Orleans, will be discussed with regulatory authorities, and remigromig is also being evaluated in the ongoing pivotal Phase 2b/3 BAROLO study in DME and a Phase 2 proof-of-concept study in NVAMD and RVO.

Jim Cramer said $30 is a good level to buy Chipotle Mexican Grill, telling a Mad Money caller on October 7 that he is probably one of the few people who thinks so. Chipotle reported second-quarter revenue of approximately $3.3 billion, up 9.3%, with comparable restaurant sales up 2.2% on a 1% increase in transactions and a 1.2% rise in average check, and management raised its full-year comparable-sales outlook to low-single-digit growth while maintaining plans for 350 to 370 restaurant openings. Profitability has not kept pace: food, beverage and packaging costs rose to 29.7% of revenue from 28.9%, labor costs rose to 25% from 24.7%, quarterly net income fell to $403.5 million from $436.1 million, and adjusted diluted EPS was unchanged at $0.33. On October 8, Chipotle shares rose approximately 6% after a report that Starbucks had explored a takeover, though Starbucks declined to comment and no acquisition agreement was announced. The stock trades at approximately 25.8x forward earnings, versus 17.9x for McDonald's and 22.4x for Yum! Brands, while hedge fund holders fell to 63 in the second quarter from 68 in the first, with Arrowstreet Capital the most prominent holder at 24.24 million shares and short interest at 3.60% of the public float.

Veeva Systems is drawing renewed attention after Eli Lilly committed to deploying its Vault CRM globally in August and Amgen followed in September, moving established customers onto the company's newer commercial platform. For the quarter ended July 31, Veeva reported revenue up 18% to $928 million, including 16% subscription growth, while GAAP operating income rose 40% to $275 million and adjusted diluted EPS climbed to $2.35 from $1.99. The company's updated full-year outlook calls for approximately $3.68 billion in revenue and adjusted diluted EPS of approximately $9.21. Veeva shares trade at roughly 29.7x forward earnings versus 15.5x for Salesforce, and the stock returned 61.1% between March 30 and October 5. Insider Monkey tracked 61 hedge funds holding Veeva in the second quarter, down from 62 in the first, with short interest at 3.35% of float.